Pandorum Technologies, operating in India and the United States, has built a proprietary platform that integrates biology, engineering and computation to create tunable exosome therapies capable of reprogramming pathological tissue states such as inflammation and fibrosis. Its lead product, Kuragenx, targets ocular surface diseases—including Stevens–Johnson Syndrome and Neurotrophic Keratitis—and has received U.S. FDA Orphan Drug Designation. The company’s broader vision is to scale from single-tissue repair to multi-tissue regeneration, ultimately enabling patients to "heal fast and age slow." To support commercialization, Pandorum has established a distributed manufacturing strategy, working with AGC Biologics in Italy for U.S. and European markets and Nucelion Therapeutics (a Bharat Biotech subsidiary) for Asia-Pacific supply, while evaluating partnerships in the Middle East. Future plans include expanding the platform to treat inflammatory and degenerative conditions affecting the lung, liver and nervous systems. The newly secured US$18 million Series B financing positions the company to advance clinical programs, scale production and enlarge its global footprint.

Total raised

$42M

Funding rounds

4

Latest round

Series B

Latest activity

Feb 2026